Novel ADC Target Hunting in Pediatric AML – Module 4
Released On
March 13, 2023
Expires On
March 12, 2024
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology, Pediatrics
Topic(s)
Leukemia, Oncology, Pediatrics, Pharmacology
This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of key data and ongoing clinical trials investigating the development and use of antibody-drug conjugates (ADC) targeting different myeloid markers for the treatment of pediatric acute myeloid leukemia (AML).
Learning Objective
Upon completion of this activity, participants should be better able to:
- Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML)
Faculty
Soheil Meshinchi, MD, PhD
Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA
Soheil Meshinchi, MD, PhD, is a Full Member at the Fred Hutchinson Cancer Center (FHCRC) and a professor of pediatrics at the University of Washington in Seattle, WA. Dr Meshinchi received his medical degree at Wayne State University School of Medicine in Detroit, MI. He then completed his residency in pediatrics at Johns Hopkins University School of Medicine in Baltimore, MD and his fellowship in pediatric hematology/oncology at the University of Washington School of Medicine in Seattle, WA.
Dr Meshinchi’s laboratory is focused on the identification and functional evaluation of molecular alterations in leukemias in order to advance novel “biomarkers” for clinical risk assessment and to be used as therapeutic targets. He is recognized worldwide as an expert in large-scale studies of genes (the genome), “RNA” molecules that are made from genes (the transcriptome), and small chemical changes that can substantially change gene, RNA, and protein activities (the epigenome) to promote leukemia formation and progression.
Dr Meshinchi, as the director of the COG Hematopoietic Integrated Translational Science Center (HM-ITSC) and the chairman of the Children’s Oncology Group (COG) AML Biology Committee, provides scientific leadership for all hematopoietic malignancies group-wide and for the AML disease committee, respectively. He has been the vice-chair for the last 2 COG AML trials and have been the PI for the BIQSFP funding mechanism for both trials. He also directs the COG AML cell and Nucleic Acid Repository and have created a robust biorepository of viable cells, plasma, and extracted nucleic acids in over 30,000 specimens from 3000 patients.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Soheil Meshinchi, MD, PhD, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Participation and Credit
In order to receive credit, users must:
- Read the learning objectives and faculty disclosure
- Participate in the activity
- Complete the activity evaluation
A statement of credit will be available to print immediately.
There is no fee to participate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
If you have questions about this activity, please contact RMEI at contact@rmei.com.